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Objective. Although many efforts have been made to generate small-diameter (5 mm) vascular grafts by means of tissue
engineering, improvement in patency and functionality still remains a great challenge. It is our hypothesis that to achieve
long-term functionality and patency, not only the complete lining with endothelial cells but also full biocompatibility is
essential.
Design. The aim was the development of a conduit from a scaffold and endothelial progenitor cells (EPC) separated from
peripheral blood of a single donor.
Materials and methods. EPC and a fibrin preparation were separated from porcine peripheral blood. Fibrin segments
were generated seeded with EPC and were perfused in a bioreactor in vitro.
Results. From 100 ml blood 12e15 cm long fibrin tubes were successfully generated lined with endothelial-like cells.
Seeded tubes showed a remarkable elasticity and burst strength up to 90 mm mercury.
Conclusions. Stable fibrin tubes were successfully generated completely lined with an endothelium-like monolayer from
fibrin and EPC, both isolated from the same volume of blood. Although their stability is not those needed for arterial graft-
ing, our results raise the hope, that with distinct improvements in future studies functional autologous vascular grafts
could be engineered from the patient’s own blood.
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The clinical use of large-calibre synthetic vascular
grafts (e.g. Dacron, PTFE) with an internal diameter
5 mm is well established. Other than for large-
diameter prosthesis increased susceptibility of syn-
thetic materials to platelet deposition, thrombosis,
anastomotic neointimal hyperplasia and foreign
body reaction in the surrounding tissue accompanied
with inferior flow conditions lead to short- or mid-
term graft failure in small-calibre vascular grafting
with an internal diameter 5 mm.1,2 Autologous ves-
sels, such as the great saphenous vein, provide better
long-term results, namely in the femoropopliteal and
the coronary artery bypass grafting.3,4 But due to
atherosclerosis and varicosis up to 30% of patients
undergoing bypass grafting do not have suitable
autologous vessels.5,6 On the other hand the number
of vascular surgical operations increases because of
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increasing prevalence of atherosclerotic arterial dis-
ease in an ageing society.7
In the last decades various attempts have been
made, to develop a bioartificial small-calibre vascular
prosthesis by means of tissue engineering.8 The seed-
ing of autologous vascular cells on an adequate
scaffold material, which resists the arterial blood pres-
sure and enables vascular cells to attach and spread
on it, has thereby become the basic principle.9 A com-
plete lining of the inner surface of the conduit with
functional endothelial cells is needed to achieve its
non-thrombogenicity, and some promising results
were obtained by lining synthetic small-calibre grafts
with endothelial cells.10,11
But furthermore, recent studies indicate that also
the biocompatibility of the scaffold material plays an
important role for the long-term functionality of the
conduit.12e14 Immunological reactions against a not
compatible scaffold lead to degeneration of the con-
duit and deprivation of the functionality culminating
in graft failure, whereas a biocompatible conduit on
the other hand can be expected not to provoke
immunological reactions, but in contrast to underlieved.
34 T. Aper et al.the body’s own repair mechanisms (remodeling).15
Therefore, a complete autologous conduit seems to
be the best approach to achieve its long-term
functionality.
The objective of our efforts is the development of
a bioartificial vascular graft by means of an autolo-
gous scaffold material seeded with endothelial pro-
genitor cells (EPC). With regard to a later clinical
application, the scaffold material should be generated
easily without the need for surgical procedure to har-
vest it from the body of the later recipient. In this
study our hypothesis was reviewed whether a bioarti-
ficial vascular graft could be generated from proteins
and cells of a peripheral blood sample of one single
donor.
Methods
Both, cells and fibrinogen were separated from the
same volume of peripheral porcine blood. 100 ml
blood were drawn under sterile conditions from
pigs’ internal jugular vein and collected in hepari-
nised syringes (20 units heparin per ml). The blood
was centrifuged at 1000 g and 4 C for 20 min. The
separated plasma was aspirated gently and stored in
a sterile flask at 20 C until its subsequent use.
Generation of the fibrin segments
The fibrin tubes were generated from a fibrinogen-
component, which was separated from the previously
frozen plasma and a solution of pooled bovine throm-
bin and protamine.
Fibrinogen-component
The stored plasma was thawed gently. One tenth was
declined, mixed with calcium chloride-solution
(40 mM; Baxter, Heidelberg, Germany) at a ratio of 1
to 2.5 and stored separately in a sterile flask. Ethanol
(70 vol.%) was added to the remaining plasma up to
a concentration of 10% v/v. The solution was stored
at 4 C, and 15 min. after addition of ethanol it was
centrifuged at 1500 g for 20 min. at 4 C to separate
the fibrinogen. The supernatant was decanted and
the fibrinogen pellet dissolved gently at 37 C in the
priory separated plasma-solution.
Thrombin-component
10 ml of the thrombin-component were mixed
from 2000 units protamine (Protamine-HCl, Roche,Eur J Vasc Endovasc Surg Vol 33, January 2007Grenzach-Wyhlen, Germany), 2000 units aprotinin
(Trasylol, Bayer, Leverkusen, Germany), 500 units of
pooled bovine thrombin (Baxter) and 5 ml calcium
chloride-solution (40 mM; Baxter).
Preparation of the fibrin tubes
Both, the fibrinogen and the thrombin components
were given simultaneously in equal volumes in a
custom-built casting mould. The mould consisted of
two 15 cm long glass tubes, which were closed and
fixed at one end (Fig. 1a). The internal casting
cylinder with an outside diameter of 5 mm and the
Fig. 1. The fibrin segments were generated in a custom-built
casting mold (a). The mold consisted of two 15 cm long
glass tubes, which were closed and fixed at one end. The in-
ternal tube had an outside diameter of 5 mm and the inside
diameter of the external tube was 11 mm with a 3 mm broad
interspace among both tubes, in which the fibrin prepara-
tion was filled. Due to shrinkage during the hardening
of the fibrin preparation segments with a wall thickness of
1.5e2.5 mm were obtained. Fig. 1b shows a segment
of group A after 10 days of incubation in vitro before placing
it in the bioreactor.
35Blood Vessels Engineered from Peripheral Bloodexternal cylinder with an inside diameter of 11 mm
confined a 3 mm broad space, which was filled with
the fibrin preparation. After 15 min. the fibrin tube
was removed from the casting mould and given in
a culture flask. 50 ml Endothelial Cell Basal Medium
2 (EBM; Clonetics, Cambrex, East Rutherford, NJ,
USA) and 50,000 units aprotinin were added.
Isolation and cultivation of EPC
The monocyte fraction was separated by means of
density gradient centrifugation in 10 ml of ficoll-
preparation (Sigma, Hamburg, Germany) and 10 ml
of phosphate buffered saline (PBS) (Sigma). After cen-
trifugation at 400 g for 7 min. the buffy coat was aspi-
rated, washed twice in PBS and suspended in 10 ml
EBM. The suspension was given into a gelatine-
precoated (1% bovine gelatine; Sigma) culture flask.
Medium was changed at the following day to remove
remaining red blood cells. In the following the me-
dium was changed every second day. On day 7e10
colonies of cells with endothelial-like morphology en-
tered the stage. After reaching confluence the cells
were detached with trypsin (Sigma) and placed in
a gelatine-precoated 75 cm2-culture flask. For seeding
procedures only cells were taken from the fourth
passage.
Seeding and perfusion
13 tubes were generated and the settings were modi-
fied by the incorporation of EPC defining two groups
of experimental settings: in the first group (A) cells
were incorporated in a density of 0.8e1 106 per ml
into the fibrin preparation (n¼ 8), whereas in the sec-
ond group (B) no cells were incorporated (n¼ 5). Dis-
position was done randomly. The segments were
incubated in a culture flask for at least 10 days at
37 C and 5 vol.% CO2 before they were put in the bio-
reactor system for perfusion process. Medium was
changed every second day. Due to poor mechanical
properties of the unseeded tubes only the segments
of group A were placed in a custom-built bioreactor,
which was filled with 50 ml EBM with 20,000 units
aprotinin. Perfusion of the segments was performed
for 5 days with a roller pump (Masterflex L/S, Ponn-
dorf Gera¨tetechnik GmbH, Kassel, Germany). Perfu-
sion rate was 120 ml/min. with a mean pressure of
25 mm mercury. Perfusion medium was EBM. Both,
perfusion medium and the medium in the reactor
were refreshed every second day.Immunohistochemical characterization of the EPC
and the fibrin tubes
The affiliation of the isolated cells to the endothelial
cell lineage was proven by immunohistochemical
stanings of cytospins from the EPC’s populations
from the fourth passage and cross-sections of seeded
fibrin tubes performed for the presence of the endo-
thelial cell-specific protein von-Willebrand-factor
(vWF, monoclonal mouse, clone F8/86, DAKO Cyto-
mation, Hamburg, Germany), the NO-synthase regu-
lating enzyme caveolin-1 (polyclonal mouse, Becton
Dickinson Biosciences, clone 2297, Heidelberg, Ger-
many) and vimentin, a protein of the cytoskeleton ex-
pressed by cells of mesodermal origin (monoclonal
mouse, clone 9V, DAKO). Additionally, staining of
cross sections of the fibrin tubes were performed for
the presence of the extracellular matrix proteins lam-
inin (polyclonal DAKO) and collagen IV (monoclonal,
clone CIV22, DAKO). Staining procedure was
performed using the avidin-peroxidase-technique
(APT). A goat anti-mouse served as secondary anti-
body (DAKO). Specimens were viewed under light
microscope. Corresponding negative and positive
control staining were performed for each antibody.
Scanning electron microscope examination
Specimens of the seeded matrices were fixed by im-
mersion with glutaraldehyde 2.5% in 0.1 mmol/L ca-
codylate buffer and 2% paraformaldehyde at pH 7.4
for 24 hours. After dehydration in graded series
of ethanol solutions, the samples were dried in
critical point dryer (E 3000, Polaron). The specimens
were coated with platin-palladium (SCD 040,
Balzes, Lichtenstein) and examined under scanning
electron microscopy (SEM505, Philips/FEI, Eindhoven,
Netherlands).
Results
Fibrin tubes
From 100 ml blood approximately 50 ml plasma were
separated, and hereof 4e5 ml of the fibrinogen prepa-
ration could be separated, which were mixed with an
equal volume of the thrombin-component. Therefore,
8e10 ml of the complete fibrin preparation was given
into the casting mould (Fig. 1a). In both groups fibrin
tubes with an internal diameter of 5 mm and a length
of 12 to 15 cm were obtained (Fig. 1b). The wall thick-
ness ranged between 1.5e2.5 mm due to shrinkage
during the hardening of the fibrin segments. ElectronEur J Vasc Endovasc Surg Vol 33, January 2007
36 T. Aper et al.scanning examination revealed the reticular structure
of their wall.
Mechanical properties of the fibrin tubes
A: In the first group, the generated tubes were re-
markably flexible and elastic and could be stretched
up to 150% of their original length, before rupturing
(only tested n¼ 2). Burst strength of up to 90 mmmer-
cury (n¼ 8, median 82.0 8.7 mm) was measured.
B: In the second group, the mechanical properties
of the fibrin tubes were found to be distinct inferior
from the remarkable properties of the segments of
group A. They were found to be more rigid and al-
ready disrupted partially during their removal from
the mold, so that the burst strength could only be
measured in one setting and was less than 20 mm
mercury.
Cell isolation and culture
The cells, which were obtained by density gradient
centrifugation and cultivated in vitro, were found to
be morphologically heterogenic in size and shape dur-
ing the first week with a low ratio of core-cytoplasm
(Fig. 2a). The majority of the isolated cells died within
the first 10 days, whereas during this time in 9 of 14
settings colony-forming cells with an endothelial mor-
phology entered the stage (Fig. 2b). These colonies
reached confluence within 18 days in mean and
were expanded. Only cells in the fourth passage
were used for seeding procedures, which were found
to be positive in immunohistological staining of cyto-
spins for vWf and caveolin-1 (Fig. 2c). Confluence in
the fourth passage was obtained within 30 days after
isolation. These findings indicate that late outgrowth
endothelial cells (OEC) were obtained at the end of
expansion in vitro and were used for seeding
experiments.
Immunohistology and electron microscopic findings
Electron microscopic scanning showed a complete
coverage of the inner surface with cells with an
endothelial-like morphology (Fig. 4), which were
found to be positive for vWf, caveolin-1 and vimentin
in immunohistological staining (Fig. 3). In these seg-
ments cells positive for these markers were also found
to be spread over the complete wall. By immunohis-
tology neoformation of both matrix proteins laminin
and collagen IV was found in a small layer along
the layer of endothelial-like cells on the surface.
Semiquantitative analysis revealed the expression ofEur J Vasc Endovasc Surg Vol 33, January 2007Fig. 2. The cells, which were obtained by density gradient
centrifugation and cultivated in vitro, were found to be
morphologically heterogenic in size and shape during the
first week with a low ratio of core-cytoplasm (a) (100).
The majority of the isolated cells died within the first 10
days, whereas during this time in 9 of 14 settings colony-
forming cells with a typical endothelial morphology entered
the stage (b) (200). These colonies were grown to conflu-
ence within 18 days in mean and expanded in vitro. The
cells in the fourth passage were found to be positive in im-
munohistological stainings of cytospins for von-Willebrand-
factor and caveolin-1 (c) (200).
37Blood Vessels Engineered from Peripheral Bloodlaminin to a coherent layer, whereas collagen IV was
formed in no coherent pattern.
B: Immunohistochemical staining revealed no for-
mation of collagen IV and laminin and was negative
for vWf, caveolin-1 and vimentin.
Discussion
Although in various studies implantable bioartificial
small-calibre vascular conduits were generated with
Fig. 3. Immunohistochemical staining for von-Willebrand-
factor of a cross section of a seeded fibrin segment (group
A) 15 days after its generation (100). The inner surface
was lined with a complete monolayer of cells with an endo-
thelial cell-like morphology, which were positive in staining
for von-Willebrand-factor (vWF). Additionally, vWf-positive
cells were also found to be spread over the complete wall.
Coculture settings of endothelial and myocytic cells were
not obtained.
Fig. 4. Electron microscopic scanning showed a complete
coverage of the inner surface of the seeded fibrin segments
of group A with cells with an endothelial-like morphology
(372).good short- or mid-term results in vivo, at present
none have reached routine clinical application.11,16e20
There is strong evidence that the functionality of a vas-
cular conduit depends not only on its lining with
functional endothelial cells but also on its other
main components: the scaffold and the extracellular
matrix.21
The search for an adequate scaffold is still an
ongoing challenge in the field of tissue engineering.
Distinct studies indicate that the biocompatibility of
the scaffold is essential for long-term functionality
and patency of a vascular conduit.12e14,22,23 A fully
biocompatible graft is expected to underlie the recip-
ient body’s own repair mechanisms (remodelling),
whereas a not compatible would provoke immuno-
logical reactions, which could lead to a deterioration
of its functionality culminating in graft failure.13e15,22
Therefore, it seems to be essential to minimize syn-
thetic and allogenic components in a vascular conduit
to eliminate immunological reactions. An autologous
scaffold must be found, which provides sufficient
mechanical properties and enables vascular cells to
attach and spread on it.
Beside other proteins fibrin preparations have been
found to be an ideal scaffold for 3-dimensional seed-
ing of specific cell types in cardiovascular and other
fields of tissue engineering.20,24e30 The separation of
a fibrin preparation from peripheral blood is easy to
accomplish, and we could demonstrate here for the
first time the generation of stable fibrin tubes from
the blood of one single donor. With regard to a later
clinical use our method provides an elegant approach
due to the low volume of blood, which is needed for
their generation and the separation of an adequate
amount of progenitor cells for seeding procedures.
For the generation of 15 cm long segments with a cal-
ibre of 5 mm only 100 ml blood is needed. Only
pooled bovine thrombin was used as a potential
source of immunological reactions in a later recipient,
however, the use of autologous thrombin was de-
scribed recently.25
Poor mechanical properties have limited the fur-
ther application of protein preparations in cardiovas-
cular tissue engineering in the past. Correspondingly,
inferior stability and durability were found in our
experiments in the not seeded segments of group B.
Nevertheless, the mechanical properties of a protein
scaffold can be increased by seeding it with vascular
cells, which enhance its stability by two main mecha-
nisms: the expression of contractile filaments and the
formation of extracellular matrix proteins. In our
experiments formation of a nearly coherent layer of
laminin was found but only incoherent patterns of
collagen IV. These findings have limited significanceEur J Vasc Endovasc Surg Vol 33, January 2007
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formed. But newly formed extracellular matrix is eli-
gible with regard to higher structural integrity and
durability and a superior cellular functionality, which
has been shown to depend on cell-matrix interac-
tion.31 Stability of the seeded fibrin segments have
been found to be superior. The burst strength was in-
creased up to 90 mm mercury in the seeded segments
compared with only less than 20 in group B, in which
no formation of matrix proteins was found. Surpris-
ingly, the mechanical properties were superior al-
ready immediately after the generation of the
segments (A). At this early point no significant effect
from a formation of contractile filaments or matrix
proteins can be expected, and the mechanism leading
to the enhanced stability at this early time remains
unclear.
Coculturing arrangement of smooth muscle cells
with endothelial cells has found to be favourable in
the past with regard to an increased expression of ma-
trix proteins and enhanced cellular functionality due
to cell-cell interaction.24,32 For the purpose of arrang-
ing such a coculturing setting the expanded progeni-
tor cells were incorporated into the fibrin segments
during the casting procedure. Previous studies de-
scribed the potential of EPC to differentiate into dif-
ferent cell types including mature endothelial cells
and smooth muscle cells and their pivotal role in post-
natal angiogenesis and vascular regeneration.33e37
Due to their properties in the last years EPC have en-
tered the stage of therapeutic application including
cardiovascular tissue engineering.16,17,37,38 EPC were
found to circulate in the peripheral blood, from which
they can be separated by means of density gradient
centrifugation.39 Recent studies indicate that hetero-
geneous cell populations with diverse patterns of ex-
pression of marker proteins are obtained. Colony
forming cells with an endothelial phenotype and the
growth pattern, which was found during the expan-
sion of the isolated progenitor cells in our study
were previously termed as late outgrowth endothelial
cells (OEC). These cells represent only a small sub-
population of the EPC fraction but have found to
have a great intrinsic angiogenic capacity and consti-
tute a valuable source for therapeutic and tissue engi-
neering approaches. OEC are described to express
endothelial marker proteins as vWf and the NO-syn-
thase regulating protein caveolin-1, which were de-
tected in the cell populations we obtained from
peripheral blood, proving that cells from the endothe-
lial lineage were obtained and seeded on the fibrin
tubes.40,41
The complete lining of the inner surface with
endothelial-related cells was achieved. But theEur J Vasc Endovasc Surg Vol 33, January 2007incorporated cells inside the wall were still positive
for vWF, presuming that there was no or only less dif-
ferentiation towards a contractile mesenchymal phe-
notype. The aspired arranging of cocultures of cells
with an endothelial and a myocytic phenotype was
not obtained accompanied with mechanical proper-
ties, which are not sufficient for arterial bypass graft-
ing. This result shows that it is not effectual for
obtaining coculture settings to seed only OEC on a fi-
brin scaffold. To accomplish coculture settings in fu-
ture experiments the differentiation of the isolated
progenitor cells should be influenced towards a myo-
cytic phenotype during expansion by the selective ap-
plication of growth factors as was found previously
for platelet-derived growth factor.35
In conclusion we developed a simple method for
the construction of vascular conduits from the periph-
eral blood of one single donor. Although the obtained
stability of the engineered segments did not reach
those, which were needed for the use for arterial by-
pass grafting, our results raise the hope that with dis-
tinct advancements including selective influencing of
the differentiation of the separated cells, this method
will lead to implantable vascular segments.
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